Fluticasone furoate
[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-Difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
Drag to rotate. Structure from PubChem CID 9854489.
Background
Listing
- Schedules
- Schedule 2 to 4, conditions apply
- Source
- Consolidated Schedules 06 July 2026
Registered medicines
3 registered products listed
Counted through the register's ingredient index, which does not reach every record.
| Name | Brands | Dosages | Applicants | Registrations | Schedule |
|---|---|---|---|---|---|
| Fluticasone furoate | Genemist, Avamys, Furamist, +2 more | 27.5 _g | 3 applicants | 5 registrations | S4 |
| Fluticasone furoate, vilanterol | Revinty elipta, Relvar elipta | 92/22 ug, 184/22 ug | Glaxosmithkline South Africa (Pty) Limited | 4 registrations | S2 to S4conditions apply |
| Fluticasone furoate, umeclidinium, vilanterol | Trelegy ellipta, Elebrato ellipta | 100 μg/ 62,5 μg/ 25 μg, 100 μg/ 62,5 μg/25 μg | Glaxosmithkline South Africa (Pty) Limited | 2 registrations | S4 |
Regulatory status
Where S2 to S4 sits on the scale
Depends on which listing applies
At the least restrictive, Schedule 2: a pharmacist can sell it directly, without a prescription. At the most restrictive, Schedule 4: prescription-only medicine. The listings below say which applies to which form, strength or pack size.
Schedule S2 to S4, as the Consolidated Schedules list it.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Fluticasone furoate
S4: Fluticasone furoate
- except when intended for nasal administration, as an aqueous spray, in the short-term (less than 6 months) prophylaxis and treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to- (i) a maximum daily dose of 55 micrograms per nostril; and (ii) a maximum pack size limit of 120 doses. (S2)
- except when intended for inhalation or nasal administration. (S3)
Consolidated Schedules 06 July 2026, lines 6411 to 6421
S3: Fluticasone furoate
- when intended for inhalation or nasal administration;
- except when intended for nasal administration, as an aqueous spray in the short-term (less than 6 months) prophylaxis and treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to- (i) a maximum daily dose of 55 micrograms per nostril; and (ii) a maximum pack size limit of 120 doses. (S2)
- except when intended for administration other than by inhalation or nasal administration. (S4)
Consolidated Schedules 06 July 2026, lines 3622 to 3639
S2: Fluticasone furoate
- when intended for nasal administration, as an aqueous spray, in the short-term (less than 6 months) prophylaxis and treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to- (i) a maximum daily dose of 55 micrograms per nostril; and (ii) a maximum pack size limit of 120 doses; (S3)
- except when intended for administration other than by inhalation or nasal administration. (S4)
Consolidated Schedules 06 July 2026, lines 2033 to 2040
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.